CD8A and hematologic disorder: Moreover, the anticancer activity of the synthesized vaccine was required for CD8+ and CD11c+ DCs-mediated CD8+ T cell response, thus highlighting the potential of this vaccine strategy as a promising approach for hematological malignancy treatment.